LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Apellis Pharmaceuticals Inc

Cerrado

SectorSalud

23.78 -2.66

Resumen

Variación precio

24h

Actual

Mínimo

23.59

Máximo

24.44

Métricas clave

By Trading Economics

Ingresos

50M

-42M

Ventas

12M

178M

Margen de beneficio

-23.615

Empleados

705

EBITDA

50M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+53.26% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

724M

3.1B

Apertura anterior

26.44

Cierre anterior

23.78

Noticias sobre sentimiento de mercado

By Acuity

55%

45%

334 / 371 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 sept 2025, 17:03 UTC

Principales Movimientos del Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept 2025, 16:49 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

GD Culture Shares Drop After Deal for Pallas Capital

16 sept 2025, 16:11 UTC

Principales Movimientos del Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept 2025, 23:20 UTC

Charlas de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept 2025, 21:10 UTC

Adquisiciones, fusiones, absorciones

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept 2025, 20:51 UTC

Charlas de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 20:25 UTC

Ganancias

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept 2025, 20:24 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept 2025, 19:19 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept 2025, 18:52 UTC

Charlas de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept 2025, 18:38 UTC

Charlas de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept 2025, 18:19 UTC

Charlas de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept 2025, 18:01 UTC

Charlas de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept 2025, 17:34 UTC

Charlas de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept 2025, 16:53 UTC

Ganancias

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 16:15 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Commodities Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept 2025, 15:22 UTC

Charlas de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept 2025, 15:21 UTC

Charlas de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

53.26% repunte

Estimación a 12 meses

Media 37.38 USD  53.26%

Máximo 60 USD

Mínimo 19 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

10

Comprar

7

Mantener

0

Vender

Sentimiento

By Acuity

334 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat